Entries by Maui Derm News

Update on Psoriasis Comorbidities: Now That We Know What We Know, How Does It Change What We Do

Based on the Maui Derm 2018 presentation by Joel M. Gelfand MD, MSCE, FAAD, from University of Pennsylvania Perelman School of Medicine, Philadelphia Pennsylvania Article by Jo Ann LeQuang and the Journal of Clinical and Aesthetic Dermatology Medical literature on the topic of psoriasis comorbidities has been rapidly expanding since around the turn of the […]

New Developments in the Treatment of Moderate-to-severe Psoriasis: Biologics

Based on the Maui Derm 2018 presentation by Craig L. Leonardi, MD, Associate Clinical Professor of Dermatology, St. Louis University Medical School, St. Louis, Missouri Article by Jo Ann LeQuang and the Journal of Clinical and Aesthetic Dermatology Cytokines, those small proteins that regulate specific activities of a wide range of immunocompetent cells, are only […]

Update on the Pathogenesis of Psoriasis: A Bench-to-Bedside Success Story

Based on the Maui Derm 2018 presentation by Andrew Blauvelt, MD, MBA, Oregon Medical Research Center, Portland, Oregon Article by Jo Ann LeQuang and the Journal of Clinical and Aesthetic Dermatology Psoriasis is caused by the complex interplay of four factors: autoantigens, environmental antigens, genetics, and the immune system. Autoinflammation, an inflammatory state not mediated […]

Psoriasis: New Data for 2018

Based on the Maui Derm 2018 presentation by Bruce E. Strober, MD, PhD, Professor and Chair, University of Connecticut Health Center, Department of Dermatology, Farmington, Connecticut Article by Jo Ann LeQuang and the Journal of Clinical and Aesthetic Dermatology Four significant studies emerge when perusing the new data from 2017, all of which can help […]

New Drugs, New Devices

By Ted Rosen, MD The year 2017 saw many new drugs and devices introduced that show considerable promise for dermatology patients. A fast round-up of what was approved in 2017 (including one December 2016 entry) appears in Table 1. Table 1. Drug Brand Approval Date Indication/Area What’s New Crisaborole Eucrisa® 12/14/16 Atopic dermatitis Good safety […]

Pediatric Acne: Putting Best Practices into Actual Practice

By Lawrence F. Eichenfield, MD Restaurants do it all of the time—something changes and the restaurant must understand the change, adapt to it, and make changes to its system. Changes may seem unimportant—a decrease in local foot traffic, changes in customer preferences for certain foods—but they can impact business. When the change is well managed, […]

Cutaneous tolerability of a novel topical minocycline gel for the treatment of rosacea

Cutaneous tolerability of a novel topical minocycline gel for the treatment of rosacea Presenters: Bhatia N1, Ahmadyar M1, Hansra H2, Del Rosso J3, Baldwin H4, Daniels AM5 Affiliations: 1Therapeutics Clinical Research, San Diego, CA; 2BioPharmX, Inc., Menlo Park, CA; 3JDR Dermatology Research, LLC, Las Vegas, NV; 4The Acne Treatment and Research Center, Morristown, NJ Background/Objective: […]

Concurrent administration of ivermectin 1% cream with brimonidine 0.33% gel improves efficacy and tolerability in treatment of moderate-to-severe rosacea

Concurrent administration of ivermectin 1% cream with brimonidine 0.33% gel improves efficacy and tolerability in treatment of moderate-to-severe rosacea Presenters: Gold LS1, Papp K2, Lynde C3, Lain E4, Gooderham M5, Johnson S6, Kerrouche N7, Schäfer G8 Affiliations: 1Department of Dermatology, Henry Ford Medical Center, Detroit, MI; 2K. Papp Clinical Research, Probity Medical Research, Waterloo, ON, […]